None
Quote | Allogene Therapeutics Inc. (NASDAQ:ALLO)
Last: | $2.16 |
---|---|
Change Percent: | 1.72% |
Open: | $2.29 |
Close: | $2.16 |
High: | $2.29 |
Low: | $2.125 |
Volume: | 3,052,596 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Allogene Therapeutics Inc. (NASDAQ:ALLO)
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
2024-06-12 13:09:17 ET Summary Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026. Results from phase 2 ALPHA2 trial, using cema-cel f...
Message Board Posts | Allogene Therapeutics Inc. (NASDAQ:ALLO)
Subject | By | Source | When |
---|---|---|---|
An oral presentation at AACR next month https://www.abstractsonline.com/pp8/#!/1 | jondoeuk | investorshub | 03/22/2023 9:14:22 PM |
A proprietary approach to control rejection https://www.globenewswire.com/news-r | jondoeuk | investorshub | 03/22/2023 9:12:05 PM |
R&D showcase PR https://www.globenewswire.com/news-release/2022/11/29/2564467/0/ | jondoeuk | investorshub | 03/22/2023 9:09:42 PM |
ASGCT PR https://www.globenewswire.com/news-release/2022/05/19/2446950/0/en/Allo | jondoeuk | investorshub | 05/19/2022 5:36:05 PM |
New preclinical data https://aacrjournals.org/cancerrescommun/article/2/3/158/68 | jondoeuk | investorshub | 03/24/2022 3:08:02 AM |
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in th...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...